Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

447 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy.
Landis CS, Ghabril M, Rustgi V, Di Bisceglie AM, Maliakkal B, Rockey DC, Vierling JM, Bajaj J, Rowell R, Santoro M, Enriquez A, Jurek M, Mokhtarani M, Coakley DF, Scharschmidt BF. Landis CS, et al. Among authors: di bisceglie am. Dig Dis Sci. 2016 Jun;61(6):1728-34. doi: 10.1007/s10620-016-4031-7. Epub 2016 Jan 19. Dig Dis Sci. 2016. PMID: 26781427
DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Verna EC, Morelli G, Terrault NA, Lok AS, Lim JK, Di Bisceglie AM, Zeuzem S, Landis CS, Kwo P, Hassan M, Manns MP, Vainorius M, Akushevich L, Nelson DR, Fried MW, Reddy KR. Verna EC, et al. Among authors: di bisceglie am. J Hepatol. 2020 Sep;73(3):540-548. doi: 10.1016/j.jhep.2020.03.031. Epub 2020 Mar 31. J Hepatol. 2020. PMID: 32243960 Free article. Clinical Trial.
Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.
Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. Treem WR, et al. Among authors: di bisceglie am. Drug Saf. 2021 Feb;44(2):133-165. doi: 10.1007/s40264-020-01014-2. Epub 2020 Nov 3. Drug Saf. 2021. PMID: 33141341 Free PMC article. Review.
Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development.
Regev A, Avigan MI, Kiazand A, Vierling JM, Lewis JH, Omokaro SO, Di Bisceglie AM, Fontana RJ, Bonkovsky HL, Freston JW, Uetrecht JP, Miller ED, Pehlivanov ND, Haque SA, Harrison MJ, Kullak-Ublick GA, Li H, Patel NN, Patwardhan M, Price KD, Watkins PB, Chalasani NP. Regev A, et al. Among authors: di bisceglie am. J Autoimmun. 2020 Nov;114:102514. doi: 10.1016/j.jaut.2020.102514. Epub 2020 Aug 5. J Autoimmun. 2020. PMID: 32768244 Free article. Review.
Risk factors for hepatocellular carcinoma in patients with cirrhosis.
Sarbah SA, Gramlich T, Younoszai A, Osmack P, Goormastic M, Grosso L, Cooper JN, Di Bisceglie A, Seneca R, Younossi ZM. Sarbah SA, et al. Among authors: di bisceglie a. Dig Dis Sci. 2004 May;49(5):850-3. doi: 10.1023/b:ddas.0000030098.75759.32. Dig Dis Sci. 2004. PMID: 15259508
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW; ION-3 Investigators. Kowdley KV, et al. N Engl J Med. 2014 May 15;370(20):1879-88. doi: 10.1056/NEJMoa1402355. Epub 2014 Apr 10. N Engl J Med. 2014. PMID: 24720702 Free article. Clinical Trial.
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study.
Evon DM, Stewart PW, Amador J, Serper M, Lok AS, Sterling RK, Sarkar S, Golin CE, Reeve BB, Nelson DR, Reau N, Lim JK, Reddy KR, Di Bisceglie AM, Fried MW. Evon DM, et al. PLoS One. 2018 Aug 1;13(8):e0196908. doi: 10.1371/journal.pone.0196908. eCollection 2018. PLoS One. 2018. PMID: 30067745 Free PMC article. Clinical Trial.
447 results